Advertisement

Cipla receives a warning letter from USFDA for its Goa manufacturing unit

The US Food and Drug Administration (USFDA) has issued a warning letter to Cipla’s Goa manufacturing facility.

Advertisement

In a regulatory filing with Stock Exchange, the company said, “Further to our earlier communication on the Goa manufacturing facility inspection conducted from September 16-27, 2019, by the US Food and Drug Administration (USFDA), the company has received a warning letter from USFDA.”

“It is committed to maintaining high standards of compliance and will work closely with the agency to comprehensively address all the observations,” the filing said.

Advertisement

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More